[go: up one dir, main page]

NO950297L - Prolinamidderivater - Google Patents

Prolinamidderivater

Info

Publication number
NO950297L
NO950297L NO950297A NO950297A NO950297L NO 950297 L NO950297 L NO 950297L NO 950297 A NO950297 A NO 950297A NO 950297 A NO950297 A NO 950297A NO 950297 L NO950297 L NO 950297L
Authority
NO
Norway
Prior art keywords
prolinamidderivater
salt
usuful
hydrate
chem
Prior art date
Application number
NO950297A
Other languages
English (en)
Other versions
NO950297D0 (no
Inventor
Masahiro Ohshima
Norimichi Iwase
Shigeo Sugiyama
Koichi Sugawara
Misao Okitsu
Yoshikuni Tamao
Yasuhiro Morinaka
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Publication of NO950297D0 publication Critical patent/NO950297D0/no
Publication of NO950297L publication Critical patent/NO950297L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Et prollnamidderivat repres- entert ved formel (I): (CH2) N C=0 i. CNCHj R2 ¿A-R3 (D eller et salt eller hydrat derav eller et farmasøytisk akseptabelt salt derav, som har proteaseinhiberende aktivitet og er anvendbart som aktiv bestanddel i farmasøytiske preparater, er tilveie- brakt.
NO950297A 1994-01-27 1995-01-26 Prolinamidderivater NO950297L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP773394 1994-01-27

Publications (2)

Publication Number Publication Date
NO950297D0 NO950297D0 (no) 1995-01-26
NO950297L true NO950297L (no) 1995-07-28

Family

ID=11673914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950297A NO950297L (no) 1994-01-27 1995-01-26 Prolinamidderivater

Country Status (16)

Country Link
US (1) US5744487A (no)
EP (1) EP0669317B1 (no)
KR (1) KR950032114A (no)
CN (1) CN1066712C (no)
AT (1) ATE223378T1 (no)
AU (1) AU1025795A (no)
CA (1) CA2140598C (no)
DE (1) DE69528005T2 (no)
ES (1) ES2182852T3 (no)
FI (1) FI950309A (no)
HU (1) HUT72062A (no)
NO (1) NO950297L (no)
NZ (1) NZ270395A (no)
RU (1) RU95101048A (no)
TW (1) TW306917B (no)
ZA (1) ZA95631B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
US5932567A (en) * 1995-02-10 1999-08-03 Basf Aktiengesellschaft Thrombin inhibitors
EA199700186A1 (ru) * 1995-02-17 1998-02-26 Басф Акциенгезельшафт Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
CA2176414A1 (en) * 1995-05-18 1996-11-19 S. David Kimball Acyl guanidine and amidine prodrugs
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
EA000966B1 (ru) * 1995-07-26 2000-08-28 Мицубиси Кемикал Корпорейшн Производные пеницилламинамида
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
AU1990197A (en) * 1996-03-12 1997-10-01 Bristol-Myers Squibb Company Carbamyl guanidine and amidine prodrugs
US5811402A (en) * 1996-03-22 1998-09-22 Eli Lilly And Company Antithrombotic diamides
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
CA2258915A1 (en) * 1996-06-25 1997-12-31 Michael Robert Wiley Anticoagulant agents
US6200967B1 (en) 1996-06-25 2001-03-13 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
US6117897A (en) * 1997-11-19 2000-09-12 Mitsubishi Chemical Corporation 1/2 sulfate of a [(S) -1- [(S) -2- [(trans-4- aminocyclohexylmethyl) carbamoyl]pyrrolidine-1-carbonyl]- 2-isopropylthio-2-methylpropyl]carbamic acid propyl ester
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
SE9802939D0 (sv) 1998-09-01 1998-09-01 Astra Ab New process
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
ES2295004T3 (es) 1999-01-13 2008-04-16 Astrazeneca Ab Nuevos derivados amidinobencilaminicos y su uso como inhibidores de trombina.
FR2791683A1 (fr) * 1999-03-30 2000-10-06 Synthelabo Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
US6316488B1 (en) * 1999-06-17 2001-11-13 Merck & Co., Inc. Antibiotic compound
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
EP1808440B1 (en) * 2000-08-11 2011-07-27 Wilex AG Non-covalent inhibitors of urokinase and blood vessel formation
IL149042A0 (en) * 2000-08-11 2002-11-10 Corvas Int Inc Non-covalent inhibitors of urokinase and blood vessel formation
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
WO2002062829A1 (fr) * 2001-02-02 2002-08-15 Chugai Seiyaku Kabushiki Kaisha Derives de peptide
US7195759B2 (en) * 2001-06-06 2007-03-27 The University Of Manitoba Therapeutic uses of glandular kallikrein
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
CA2478409C (en) 2002-03-11 2012-07-31 Curacyte Ag Inhibitors of urokinase, their preparation and use
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
DE10234058A1 (de) * 2002-07-26 2004-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Benzoesäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102005044319A1 (de) 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
CN101033209B (zh) * 2006-03-09 2014-08-27 上海医药工业研究院 药物中间体(2s,4r)-4-羟基-n,n-二甲基-2-吡咯烷甲酰胺的制备方法
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
CN103403018B (zh) * 2010-12-21 2015-08-19 医药公司（莱比锡）有限公司 胰蛋白酶样丝氨酸蛋白酶抑制剂,它们的制备以及作为凝结因子IIa和Xa的选择性抑制剂的用途
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
ES2625548T3 (es) 2012-06-04 2017-07-19 DiaMedica Therapeutics Inc. Isoformas de glicosilación de la calicreína-1 tisular humana
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
WO2024169765A1 (zh) * 2023-02-16 2024-08-22 上海华汇拓医药科技有限公司 一种二肽类化合物的盐、其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0813834B2 (ja) * 1990-08-01 1996-02-14 日東紡績株式会社 トリペプチド誘導体及びそれを有効成分とする蛋白分解酵素阻害剤
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
ATE171709T1 (de) * 1992-02-14 1998-10-15 Corvas Int Inc Inhibitoren der thrombose
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors

Also Published As

Publication number Publication date
ZA95631B (en) 1995-10-05
DE69528005T2 (de) 2003-04-17
ES2182852T3 (es) 2003-03-16
NO950297D0 (no) 1995-01-26
CN1066712C (zh) 2001-06-06
ATE223378T1 (de) 2002-09-15
FI950309A (fi) 1995-07-28
DE69528005D1 (de) 2002-10-10
CA2140598C (en) 2010-03-09
HU9500240D0 (en) 1995-03-28
AU1025795A (en) 1995-08-03
TW306917B (no) 1997-06-01
RU95101048A (ru) 1996-10-27
CN1121068A (zh) 1996-04-24
NZ270395A (en) 1997-06-24
EP0669317B1 (en) 2002-09-04
FI950309A0 (fi) 1995-01-24
HUT72062A (en) 1996-03-28
KR950032114A (ko) 1995-12-20
US5744487A (en) 1998-04-28
EP0669317A1 (en) 1995-08-30
CA2140598A1 (en) 1995-07-28

Similar Documents

Publication Publication Date Title
NO950297D0 (no) Prolinamidderivater
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
WO2001072728A3 (en) Novel piperazine derivatives
DK1104760T3 (da) Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
ATE297203T1 (de) Antithrombotische mitteln
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DK1104759T3 (da) Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
EP1026162A4 (en) ANTI-RHUMATISMAL AGENT
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
PT855398E (pt) Derivados sasquiterpeno tendo actividade antiviral
FI964303A0 (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine
AP2002002595A0 (en) Heterocyclic amide derivatives.
HUT75124A (en) Use of bicyclolactam derivatives for producing pharmaceutical compositions having anxiolytic activity
CA2187402A1 (en) Quinoxaline Derivatives for Treating Tinnitus
ATE319452T1 (de) Arzneimittel gegen essstörungen
EP1210948B8 (en) Therapeutic peptide for nervous diseases
ES2116528T3 (es) Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.
ATE154243T1 (de) Hemmstoff der blutgefässhypertrophie